The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

Britain's bobsledder Arran Gulliver has been provisionally suspended following a doping test failure, the International ...

Abstract Highlights ORIC-944 is a potent, highly selective, orally bioavailable, allosteric inhibitor of PRC2 that demonstrates best-in-class drug properties, including potency, solubility, and ...

A receding hairline may be common — about two-thirds of men start losing their hair by age 35 — but that doesn’t make it any ...

SaveHealth provides an overview of DHT shampoos, including pros, cons, and what kinds of issues they best solve.

As we observe Endometriosis Awareness Month in March, let us take a look at 7 biotech companies advancing promising ...

Angle updates on AstraZeneca development work and Eisai’s phase 2 pilot study: London Tuesday, March 25, 2025, 11:00 Hrs [IST] Angle Inc, a world-leading liquid biopsy company w ...

We all know that our scalp hair grays and thins as we age, but did you know that your body hair experiences serious changes, ...

Increasing cancer prevalence, including prostate cancer and neuroendocrine tumors, advances in nuclear medicine in the field ...

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for ...